GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » Capex-to-Revenue

Fisher & Paykel Healthcare (NZSE:FPH) Capex-to-Revenue : 0.34 (As of Sep. 2023)


View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Fisher & Paykel Healthcare's Capital Expenditure for the six months ended in Sep. 2023 was NZ$-275.50 Mil. Its Revenue for the six months ended in Sep. 2023 was NZ$815.80 Mil.

Hence, Fisher & Paykel Healthcare's Capex-to-Revenue for the six months ended in Sep. 2023 was 0.34.


Fisher & Paykel Healthcare Capex-to-Revenue Historical Data

The historical data trend for Fisher & Paykel Healthcare's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare Capex-to-Revenue Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.13 0.10 0.10 0.13

Fisher & Paykel Healthcare Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.12 0.18 0.10 0.34

Competitive Comparison of Fisher & Paykel Healthcare's Capex-to-Revenue

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fisher & Paykel Healthcare's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Capex-to-Revenue falls into.



Fisher & Paykel Healthcare Capex-to-Revenue Calculation

Fisher & Paykel Healthcare's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-211.3) / 1588.6
=0.13

Fisher & Paykel Healthcare's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-275.5) / 815.8
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fisher & Paykel Healthcare  (NZSE:FPH) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Fisher & Paykel Healthcare Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Traded in Other Exchanges
Address
15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.